Nephrology

With the population aging, there is a need for new treatments in nephrology.

Therapeutic candidate Sparsentan could expand treatment options for 2 rare kidney diseases. Dr. Jula Inrig expands on the potential for the FSGs patient population.

The results show serum IgA-IgG immune complex levels decreased in both patients treated with atacicept 25 mg ab atacicept 75 mg over time.

Ardelyx was issued a Complete Response Letter in July requestion an additional trial.

Dr. Jula Inrig explains the mechanism of action for the Dual Endothelin Angiotensin Receptor Antagonist (DEARA) investigational candidate Sparsentan, for rare kidney diseases.

Dr. Jula Inrig highlights the key data presented at ASN Kidney Week on investigational candidate Sparsentan for IgA nephropathy.

The treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.

Low sodium intake is considered less than 2.3 grams per day.

Dr. Demirjian explained suggested changes to how dialysis is conducted in hospital settings.

In a late-breaking abstract presented at ASN 2022, dapagliflozin attenuated the decline in eGFR between month 1-36 compared to placebo.

Investigators evaluated how the risk of kidney failure and death affects US veterans with chronic kidney disease (CKD) in research presented at Kidney Week 2022 ASN Annual Meeting.

There are plans for a larger sized study testing zetomipzomib in patients with lupus nephritis.

In a late-breaking abstract, investigators observed a 28% reduction in kidney disease progression or cardiovascular deaths compared to placebo.

With the population aging, there is a need for more home environmental treatment options for patients with kidney disease.

New research presented at Kidney Week 2022 ASN Annual Meeting, demonstrates an association between albuminuria and risk of cognitive problems.

A significantly higher number of patients receiving voclosporin achieved good renal outcome when compared with placebo.

In a late-breaking abstract, investigators assess how pantoprazole 40 mg daily effects long-term kidney function.

In a late-breaking abstract, investigators assess how discontinuation of ACEi or ARBs impact disease progression for advanced CKD.

The study shows vitamin D levels do not necessarily forecast the risk of cardiovascular disease in patients with chronic kidney disease.

In the last 20 years, most were adult studies which indicates a need for pediatric research activity, especially considering the potential that targeted therapies have for treating chronic kidney disease in children.

Approximately 1 out of every 6 patients with COVID-19 had a reduced eGFR.

Females generally have a lower risk of cardiovascular disease compared to males.

Data presented during ASN 2022 shows how heart failure impacts risk factors for renal outcomes of patients with chronic kidney disease.

Dr. Neera Dahl explains that patients with autosomal dominant polycystic kidney disease (ADPKD) are often referred to a nephrologist when imaging is done for another concern.

The common inherited condition autosomal dominant polycystic kidney disease (ADPKD) remains elusive when presented in primary care due to its nonspecific symptoms.

It is the first FDA-approved product indicated to improve kidney function in adults with HRS.

In the first episode of our monthly series, cardiologists Jorge Plutzky, MD, and Michael Farkouh, MD, interview nephrologist Matthew Weir, MD.

Temperatures changes between summer and the rest of the year correlated with the magnitude of decrease in renal function during summer.

The investigational therapy is being evaluated in a phase 2 study for the reduction in risk of major thrombotic cardiovascular events in patients with ESRD on hemodialysis.

Investigators identified a correlation between severity of kidney-urinary tract complications and the affected protein involved with intermediate junctional epidermolysis bullosa (JEB).